Last reviewed · How we verify
Exenatide twice daily (BID)
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose.
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Exenatide twice daily (BID) |
|---|---|
| Also known as | Byetta |
| Sponsor | Eli Lilly and Company |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the natural incretin hormone GLP-1. It binds to GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing hepatic glucose production. This results in improved glycemic control in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
- Headache
- Injection site reactions
Key clinical trials
- Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects (PHASE1)
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
- The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS (PHASE4)
- Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM (PHASE4)
- Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes (NA)
- Impact of Exenatide on Sleep Duration
- Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exenatide twice daily (BID) CI brief — competitive landscape report
- Exenatide twice daily (BID) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI